Fed Regist. 2001 Aug 2;66(149):40111-6.
Pursuant to its 3-0 vote to do so, the Consumer Product Safety Commission (CPSC or Commission) is issuing a rule to require child-resistant (CR) packaging on drugs (OTC switched drugs) approved by the Food and Drug Administration (FDA) for over-the-counter (OTC) sale that contain active ingredients previously available only in prescription drugs. Current Commission regulations require CR packaging for most oral drug products containing prescription-only active ingredients.However, prior to issuance of this rule there was no general requirement to maintain CR packaging of such drug products in forms subsequently approved by the FDA for OTC sale. The Commission is also revoking the current prohibition on granting a petition for an exemption from a CR packaging requirement prior to FDA approval of the drug product in question. The Commission takes these actions under authority of the Poison Prevention Packaging Act of 1970, as amended.
根据其3比0的投票结果,消费品安全委员会(CPSC或委员会)正在发布一项规则,要求对美国食品药品监督管理局(FDA)批准用于非处方(OTC)销售、含有以前仅在处方药中可用的活性成分的药品(非处方转换药品)采用儿童防开启(CR)包装。委员会现行法规要求对大多数含有仅处方用活性成分的口服药品采用CR包装。然而,在本规则发布之前,对于此类药品以随后经FDA批准用于OTC销售的形式保持CR包装并无一般要求。委员会还正在撤销当前在FDA批准相关药品之前禁止批准免除CR包装要求的请愿书的规定。委员会根据经修订的1970年《预防中毒包装法》的授权采取这些行动。